European Commission seeks to resolve shortages of radioisotopes for nuclear medicine

8 August 2010

In order to resolve the urgent issue of a shortage of supply of radioisotopes for nuclear medicine, last Friday, the European Commission adopted a Communication to the European Parliament and to the Council on medical applications of ionizing radiation, proposing a way forward to resolve the situation.

The Communication also identifies key issues to improve radiation protection of patients and medical staff, to avoid a rise in population exposure associated with the technological advances in X-ray computed tomography imaging (CT) and an increase of accidental or unintended exposures in radiotherapy. This Communication was jointly proposed by Gunther Oettinger, Commissioner responsible for Energy, and by John Dalli, Commissioner responsible for Health and Consumer Policy.

Commissioner Oettinger said: "Nuclear medicine is essential for diagnosis and treatment of serious diseases like cancer, cardiovascular and brain diseases. At the same time, the overall population exposure to ionizing radiation due to medical procedures overwhelms any other man-made exposure." Commissioner Dalli added that "the shortage of radioisotopes needed for medical procedures, as well as the need to improve patient and health professionals protection against accidental or unintended exposures in radio therapy, are important objectives of public health policy.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical